The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

China Cord Blood Corp

NYSE: CO
Last

(U.S.) $5.54

Today's change+0.10 +1.84%
Updated July 31 4:02 PM EDT. Delayed by at least 15 minutes.
 

China Cord Blood Corp

NYSE: CO
Last

(U.S.) $5.54

Today's change+0.10 +1.84%
Updated July 31 4:02 PM EDT. Delayed by at least 15 minutes.

China Cord Blood Corp up sharply

China Cord Blood Corp closed up sharply Friday, rallying (U.S.)$0.10 or 1.84% to (U.S.)$5.54. Shares have lost 3.99% over the last five days, but have gained 22.57% over the last year to date. This security has outperformed the S&P 500 by 14.69% during the last year.

Key company metrics

  • Open(U.S.) $5.45
  • Previous close(U.S.) $5.44
  • High(U.S.) $5.59
  • Low(U.S.) $5.45
  • Bid / Ask-- / --
  • YTD % change+22.57%
  • Volume173,583
  • Average volume (10-day)183,256
  • Average volume (1-month)281,560
  • Average volume (3-month)303,577
  • 52-week range(U.S.) $4.10 to (U.S.) $7.24
  • Beta1.05
  • Trailing P/E23.41×
  • P/E 1 year forward26.38×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.24
Updated July 31 4:02 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.60%Sector:HealthcareIndustry:Healthcare Facilities
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue163167152153
Total other revenue--------
Total revenue163167152153
Gross profit129131122124
Total cost of revenue34363030
Total operating expense113999593
Selling / general / administrative76606261
Research & development3222
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income50685760
Interest income (expense), net non-operating-25-26-25-25
Gain (loss) on sale of assets--------
Other--------
Income before tax29473742
Income after tax17342730
Income tax, total12141012
Net income17332730
Total adjustments to net income--------
Net income before extra. items17332730
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items17332730
Inc. avail. to common incl. extra. items17332730
Diluted net income17332730
Dilution adjustment------0
Diluted weighted average shares73737373
Diluted EPS excluding extraordinary itemsvalue per share0.230.460.370.41
Dividends per sharevalue per share--------
Diluted normalized EPSvalue per share0.230.460.370.41